Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Decline in activities of daily living predicts HF hospitalization, death

18 Apr 2019

A decline in activities of daily living (ADL) appears to predict being hospitalized for heart failure (HF) and death in HF patients, a recent study suggests.

Drawing from the Kitakawachi Clinical Background and Outcome of Heart Failure Registry, researchers enrolled 923 HF patients (mean age, 75.7±11.2 years; 54.9 percent male). ADLs were categorized into four: independent outdoor walking, independent indoor walking, indoor walking with assistance and abasia. The primary study endpoint was hospitalization for HF.

Most of the patients (89.4 percent; n=825) did not show a decline in ADL while the remaining 10.6 percent (n=98) did. Over a median follow-up period of 369 days, 30.3 percent (n=279) of the participants were hospitalized for HF.

Analysis according to ADL status showed that there were more incidences of HF hospitalization in the group of patients with vs without ADL decline (46.4 percent vs 28.4 percent). This translated to a significantly higher risk of the primary outcome, as measured by multivariable Cox proportional hazard models (hazard ratio [HR], 1.89; 95 percent CI, 1.35–2.58; p<0.001).

Over the same time period, 12.9 percent (n=119) of the overall sample had died. Mortality was likewise more common in the ADL-decline group (28.9 percent vs 11 percent), resulting in a significantly greater risk (HR, 2.67; 1.71–4.02; p<0.001).

Moreover, in a multivariate analysis including all patients, a decline in ADL again emerged as a significant predictor of HF hospitalization (HR, 1.42; 1.01–1.96; p=0.046) and death (HR, 1.95; 1.23–2.99; p<0.01).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.